2. Academic Validation
  3. Anti-inflammatory agent 35 reduces ASFV replication by suppressing the nuclear translocation of p65

Anti-inflammatory agent 35 reduces ASFV replication by suppressing the nuclear translocation of p65

  • Virology. 2025 Oct:611:110664. doi: 10.1016/j.virol.2025.110664.
Guanli Dai 1,  Yanlong Zhou 1,  Daming Song 1,  Yiping Cai 1,  Lijiao Yan 1,  Dan Li 2,  Haixue Zheng 3
Affiliations

Affiliations

  • 1 State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China; Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China.
  • 2 State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China; Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China. Electronic address: lidan@caas.cn.
  • 3 State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China; Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China. Electronic address: haixuezheng@163.com.
PMID: 40848492 DOI: 10.1016/j.virol.2025.110664
Abstract

African swine fever (ASF), caused by the African swine fever virus (ASFV), is a highly contagious infectious disease. To date, no safe and effective vaccine or therapeutic drug is available for ASFV. In this study, we identified Anti-inflammatory agent 35 (A35) as a negative regulator of ASFV replication. Real-time quantitative PCR, hemadsorption assay, and Western blotting analyses revealed that A35 inhibits ASFV genome replication and structural protein expression in vitro. Further studies demonstrated that A35 suppresses TNF-α or ASFV-triggered NF-κB signaling pathway. Reporter assays showed that A35 inhibited p65-triggered NF-κB signaling pathway. Mechanistic studies have found that A35 can inhibit the nuclear translocation of p65. Additionally, overexpression of p65 enhanced ASFV replication, whereas knockdown of p65 had opposite effects. This study reveals, for the first time, that A35 exerts its anti-ASFV effects by targeting NF-κB signal transduction, providing a theoretical basis and candidate compound for the development of novel anti-ASFV agents based on the structural optimization of natural products.

Keywords

ASFV; Anti-inflammatory agent 35; NF-κB signaling pathway; p65.

Figures
Products
Inhibitors & Agonists
Other Products